Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
Baylor College of Medicine
University of Washington
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Amgen
MacroGenics
Incyte Corporation
Trishula Therapeutics, Inc.
Dana-Farber Cancer Institute
Boehringer Ingelheim
Trishula Therapeutics, Inc.
University of California, San Francisco
Thomas Jefferson University
University of Michigan Rogel Cancer Center
Bayer
University of Kentucky
National Institutes of Health Clinical Center (CC)
Daiichi Sankyo
National Institutes of Health Clinical Center (CC)
Herlev Hospital
Henry Ford Health System
Pfizer
PrECOG, LLC.
Southern Illinois University
Roswell Park Cancer Institute
Eli Lilly and Company
Pfizer
Yale University
Northwestern University
Pfizer
Weill Medical College of Cornell University
ADC Therapeutics S.A.
Five Prime Therapeutics, Inc.
Parker Institute for Cancer Immunotherapy
Pfizer
Eli Lilly and Company
Cancer Targeted Technology
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pfizer
Rutgers, The State University of New Jersey
Pfizer
Hoffmann-La Roche
Ludwig Institute for Cancer Research
pharmaand GmbH
Herlev Hospital
Ludwig Institute for Cancer Research